Search by Medical Condition
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for Malignant Carcinoid Syndrome
- Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
- Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19
- Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial
- Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
- Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
- Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
- Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
- Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
- AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With Metastatic Well Differentiated Neuroendocrine Neoplasm
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
- Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
- Telotristat Etiprate for Carcinoid Syndrome Therapy
- Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
- An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
- P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
- Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
- TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
- Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
- Study of Panitumumab in the Treatment of Carcinoid Syndrome
- Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
- Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
- Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
- Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
- Azilect + Antidepressant Chart Review
- Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
- Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
- An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
- Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
- Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
- Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
- Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
- Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
- AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
- Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
- Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
- Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
- Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
- Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
- Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
- Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
- Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
- EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
- Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
- Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
- Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
- PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
- Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
- Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
- Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors